BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.
Looking for a particular BlueSphere Bio employee's phone or email?
The BlueSphere Bio annual revenue was $405000 in 2026.
Keir Loiacono is the CEO of BlueSphere Bio.
29 people are employed at BlueSphere Bio.
BlueSphere Bio is based in Pittsburgh, Pennsylvania.
The NAICS codes for BlueSphere Bio are [541, 54, 54171, 5417, 541714].
The SIC codes for BlueSphere Bio are [873, 87].